Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma

British Journal of Surgery

Volumn 84, Issue 6, 1997, Pages 803-807

  Ross, D A ^a   Wilson, G D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031007886     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840620     Document Type: Article

References (30)

1. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-82.
2. Vile RG. p53: a gene for all tumours? BMJ 1993; 307: 1226-7.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6.
5. Harris CC, Hollstein M. Clinical implications of the p53 tumour-suppressor gene. N Engl J Med 1993; 329: 1318-27.
6. Greenblatt MS, Bennett WP, Hollstein WP, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
7. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumour antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4: 1689-94.
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
9. Eliyahu D, Michalovitz S, Eliyahu S, Pinhasi Kimhi P, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763-7.
10. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
11. Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994; 57: 623-7.
12. Levine AJ. 11th Ernst Klenk Lecture. The p53 tumor suppressor gene and product. Biol Chem, Hoppe Seyler 1993; 374: 227-35.
13. Thor AD, Moore DH, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein; an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
14. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-31.
15. Benchimol S, Pim D, Crawford L. Radio immunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 1982; 1: 1055-62.
16. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602.
17. Bartek J, Bartkova J, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
18. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 1991; 51: 5976-9.
19. McGregor JM, Yu CC-W, Dublin EA, Barnes DM, Levison DA, MacDonald DM. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128: 606-11.
20. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53 (10 Suppl): 2235-8.
21. Kaplan EL, Meier P. Non-parametric estimation for incomplete investigations. J Am Stat Assoc 1958; 53: 457-81.
22. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
23. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972; 34: 187-220.
24. Cristolfolini M, Boi S, Girlano S et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993; 129: 739-43.
25. Akslen LA, Mørkve O. Expression of p35 protein expression in cutaneous melanoma. Int J Cancer 1992; 52: 13-16.
26. Flørenes VA, Oyjord T, Holm R et al. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 1994; 69: 253-9.
27. Trent JM, Meyskens FL, Salmon SE et al. Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med 1990; 322: 1508-11.
28. Fountain JW, Karayiorgou M, Ernstoff MS et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992; 89: 10 557-61.
29. Coleman A, Fountain JW, Nobori T et al. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 1994; 54: 344-8.
30. Pietonpol JA, Vogelstein B. No room at the p53 inn. Nature 1993; 365: 17-18.